Kejie advised 3SBio Inc. on the establishment of an investment partnership (“3SBio Ventures”) with Taizhou Oriental CMC Limited ("Taizhou Oriental").

3SBio Inc. is a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products. On February 7, 2007, 3SBio’s ADSs were successfully listed on the NASDAQ Global Market of the NASDAQ Stock Market LLC under the symbol “SSRX”.

Taizhou Oriental is the investment arm of Taizhou China Medical City, which is a Jiangsu province-based national level high-tech industrial park dedicated to life science innovation and is supported directly by the Ministry of Health, Ministry of Science and Technology and the State Food and Drug Administration.

3SBio Ventures will seek investments in the life science sector that support 3SBio's strategic interests. 3SBio Ventures will be managed by Taizhou Huan Sheng Investment Management Company Limited, a wholly-owned subsidiary of 3SBio.

Kejie team was led by partner Fred Hao and included Sun Congkun and He Fen.